O.C Suboxone understands the severity of opioid use disorder and is working to raise awareness on healthier alternatives to treat chronic pain.
Med Ad News spoke with Christian Heidbreder, Ph.D., Chief Scientific Officer of Indivior Inc., about some of the barriers to patients seeking treatment for opioid use disorder, how to integrate treatment for opioid use disorder and infectious disease services, and the company’s efforts to provide treatments for those struggling with the disorder.
The first of the Insys Therapeutics executives found guilty of violating the Racketeer Influenced and Corrupt Organizations (RICO) Act in May 2019 was sentenced to 33 months in federal prison.
Insights into former president Richard Sackler’s control of Purdue Pharma and his aggressive stance on marketing OxyContin were revealed when internal company documents were unsealed following a four-year court battle in Kentucky.
A federal judge partially overturned the convictions of Insys Therapeutics Inc.’s founder and three former executives accused of bribing doctors to prescribe an addictive opioid, but declined to disturb the remainder of the jury’s verdict.
OxyContin maker Purdue Pharma LP got court approval to reimburse millions of dollars in legal fees for states that back the company’s proposed $10 billion settlement of opioid lawsuits, but with a condition meant to help victims of the addiction crisis.
Mallinckrodt Plc received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).
Four large drug companies reached a last-minute $260 million legal settlement over their role in the U.S. opioid addiction epidemic, averting the first federal trial that was scheduled to start in Cleveland.
Indivior Plc raised the company’s full-year 2019 forecasts as the embattled British drugmaker’s best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats.
Mallinckrodt Plc hired restructuring firms and may choose to seek bankruptcy protection, Bloomberg reported, sending the drugmaker’s shares down 40 percent.